Q4 2024 SANUWAVE Health Inc Earnings Call Transcript
Key Points
- SANUWAVE Health Inc (SNWV) achieved a record revenue milestone of $10.3 million in Q4 2024, marking a 47% increase compared to the same period in 2023.
- The company experienced a 71% year-over-year growth in systems sold, with 135 systems sold in Q4 2024.
- Gross margins improved significantly to 77.9% in Q4 2024, up from 69.1% in the previous year, indicating strong operational efficiency.
- SANUWAVE Health Inc (SNWV) successfully uplisted to Nasdaq, simplifying its capital structure and strengthening its balance sheet.
- The company reported positive adjusted EBITDA of $3.7 million for Q4 2024, a substantial improvement from $0.7 million in the same period last year.
- Operating expenses increased to $5.5 million in Q4 2024, up from $3.8 million in the same period last year, largely due to non-cash stock compensation expenses.
- The company reported a net loss of $12.7 million for Q4 2024, compared to a net income of $18.2 million in Q4 2023, primarily due to changes in the fair value of derivative liabilities.
- EBITDA for Q4 2024 was negative $9.7 million, indicating challenges in achieving profitability despite positive adjusted EBITDA.
- The company faces seasonality challenges, with Q1 typically being a slower period for medical device sales, impacting revenue predictability.
- SANUWAVE Health Inc (SNWV) is still navigating the complexities of engaging with larger customers, which may lead to variability in order sizes and potential revenue lumpiness.
Good day, everyone, and welcome to today's Sanuwave earnings call. (Operator Instructions) Please note today's conference is being recorded. I will be standing by if you should need any assistance.
It is now my pleasure to turn the conference over to Morgan Frank, Chairman and CEO of Sanuwave.
Thank you, Margo. Good morning, everyone. Welcome to Sanuwave's fourth quarter and full year 2024 earnings call.
Our Form 10-K was filed with the SEC last night. Our earnings release was issued this morning, and our updated presentation was made available on the website in our investors section, you can please refer to that during the presentation. Joining me on this call is Peter Sorensen, our CFO. And after the presentation, we'll open the call up to Q&A. So, let me begin with the obligatory, forward-looking statements.
This call may contain forward-looking statements such as statements relating to future financial results, production expectations and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
